Cited by 379interferon and immune responsesDrug Transport and Resistance MechanismsPhosphodiesterase function and regulation

SLC19A1 transports immunoreactive cyclic dinucleotides.

Open access
Luteijn, Rutger D., Zaver, Shivam A., Gowen, Benjamin G., Wyman, Stacia K., Garelis, Nick E., Onia, Liberty, McWhirter, Sarah M., Katibah, George E. +3 more·2019·Nature

Abstract

The accumulation of DNA in the cytosol serves as a key immunostimulatory signal associated with infections, cancer and genomic damage 1,2. Cytosolic DNA triggers immune responses by activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway 3. The binding of DNA to cGAS activates its enzymatic activity, leading to the synthesis of a second messenger, cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP)4-7. This cyclic dinucleotide (CDN) activates STING 8, which in turn activates the transcription factors interferon regulatory factor 3 (IRF3) and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), promoting the transcription of genes encoding type I interferons and other cytokines and mediators that stimulate a broader immune response. Exogenous 2'3'-cGAMP produced by malignant cells 9 and other CDNs, including those produced by bacteria 10-12 and synthetic CDNs used in cancer immunotherapy 13,14, must traverse the cell membrane to activate STING in target cells. How these charged CDNs pass through the lipid bilayer is unknown. Here we used a genome-wide CRISPR-interference screen to identify the reduced folate carrier SLC19A1, a folate-organic phosphate antiporter, as the major transporter of CDNs. Depleting SLC19A1 in human cells inhibits CDN uptake and functional responses, and overexpressing SLC19A1 increases both uptake and functional responses. In human cell lines and primary cells ex vivo, CDN uptake is inhibited by folates as well as two medications approved for treatment of inflammatory diseases, sulfasalazine and the antifolate methotrexate. The identification of SLC19A1 as the major transporter of CDNs into cells has implications for the immunotherapeutic treatment of cancer 13, host responsiveness to CDN-producing pathogenic microorganisms 11 and-potentially-for some inflammatory diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1553-0

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • cGAMP is secreted from cancer cells via SLC19A1, which induces activation of the STING pathway in recipient cells.

    “Interestingly, cGAMP is also secreted from cancer cells via SLC19A1, which induces activation of the STING pathway in recipient cells.78, 79”

    From Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer (2020) · cites this paper as [79]

    The paper says that cGAMP produced by malignant cells can activate STING in target cells, and that SLC19A1 mediates cGAMP uptake into human cells (Abstract, page not available). It does not show that cancer cells secrete cGAMP via SLC19A1; the transport it establishes is import into recipient cells. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • cGAMP is a soluble extracellular immunotransmitter produced and secreted by malignant cells.

    “Recently, a novel role of cGAMP as a soluble extracellular immunotransmitter produced and secreted by malignant cells has been identified.”
  • SLC19A1 is first known major importer of cGAMP, taken up by host cells to activate intracellular STING pathway to elicit antitumor immune response.

    “Using a genome wide CRISPR interference screen, SLC19A1, was identified as the first known major importer of cGAMP, which is taken up by host cells to activate intracellular STING pathway to elicit an antitumor immune response.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Luteijn, R. D., Zaver, S. A., Gowen, B. G., Wyman, S. K., Garelis, N. E., Onia, L., McWhirter, S. M., Katibah, G. E., Corn, J. E., Woodward, J. J., & Raulet, D. H.
Affiliations
  • University of California, Berkeley (US)
  • University of Washington (US)
  • Innovative Genomics Institute (US)
  • Aduro BioTech (United States) (US)
  • ETH Zurich (CH)
Corresponding author
Raulet, David H.
Venue
Nature
Published
2019-09-11
Volume
573
Issue
7774
Pages
434-438
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2972961341
Cited by
379
References
47
Citations by year
2026: 25 · 2025: 65 · 2024: 62 · 2023: 50 · 2022: 70 · 2021: 48 · 2020: 51 · 2019: 8
FWCI
17.98
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (1s10od018174-01, 1dp2hl141006-01)
  • National Heart, Lung, and Blood Institute (DP2-HL-141006)
  • National Cancer Institute (R01CA093678)
  • National Institute of General Medical Sciences (T32GM007266)
  • National Institute of Allergy and Infectious Diseases (R21AI137758, R01AI113041, T32AI083203, R56AI113041)
  • National Center for Research Resources (S10RR029668, S10RR027303)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
Keywords
SLC19A1, reduced folate carrier, cyclic dinucleotides, 2'-3'-cGAMP, STING activation, cGAS-STING pathway, cytosolic DNA sensing, folate transport, membrane transport, sulfasalazine, methotrexate, cancer immunotherapy, innate immunity, inflammatory diseases
MeSH terms
Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Animals, Cytosol, DNA, Humans, Inflammation, Nucleotides, Cyclic, Nucleotidyltransferases, Interferon Regulatory Factor-3, Reduced Folate Carrier Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review